Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics,…
Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims Johnson & Johnson (NYSE:JNJ) (the Company) today announced…
ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional…
New data from pivotal studies with aflibercept 8 mg New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics…
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon…
Bayer to invest a total of 60 million euros in its Ukrainian seed production site Company was part of delegation led by German Vice-Chancellor Robert Habeck to Kyiv this week…
Bayer’s Grants4Ag Program Awards 21 Crop Science Research Grants for 2023 This year’s focus lies on research to support sustainability and the development of next-generation genomic tools in agriculture /…
Internationally renowned experts form independent Bayer Bioethics Council Bayer establishes Bioethics Council Experts from different academic disciplines to provide broad external perspective and guidance on complex bioethical questions related to…
Elisabeth Moreno to join Sanofi’s Diversity, Equity and Inclusion Board Sanofi announces the appointment of Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal opportunities, to its Diversity,…
Sanofi, AstraZeneca and Sobi simplify contractual agreements Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new…
Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc. Sanofi announced today that it…
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Two studies, published in The Lancet and The…